Imaging Features and Reliability of Percutaneous Biopsy of Metanephric Adenoma of the Kidney

Journal of Computer Assisted Tomography, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Purpose: To describe imaging features of metanephric adenomas, assess the reliability a diagnosis with image-guided percutaneous renal mass biopsy, and evaluate patient survival outcomes. Materials Methods: In this IRB-approved, HIPAA-compliant retrospective study, our institution’s radiology report database was searched for term “metanephric adenoma” from 2010 to 2020. Patient information, characteristics, biopsy technique complications were recorded. Analyses per-tumor growth rate, per-procedure diagnostic rates, per-patient disease-specific metastasis-free evaluated. Results: The search yielded 8 tumors (mean diameter 2.0 cm, range 1.0 3.1 cm) in patients (median age 60.5 y, 40 66 y; 6 women) who underwent biopsies had available review. All (8/8) solitary, well-defined, hypoenhancing on post-contrast images. For those MR, 100% (5/5) demonstrated restricted diffusion. On unenhanced CT, 62.5% (5/8) hyperdense. mean tumor rate 0.7 mm/y (range: −0.1 3 mm/y) median follow-up 83.4 months 1.6 198.0 mo). Specific adenoma first found 75% (6/8) patients; repeat 2 confirming adenoma. Per-patient outcome after clinical 151.8 250.6 mo) showed survival. Conclusions: Metanephric adenomas are usually masses imaging, hyperattenuating compared parenchyma noncontrast diffusion MR. Image-guided results reliable safe.

Language: Английский

---

The Current Role of Renal Mass Biopsy

Radiologic Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

---

Safety and Diagnostic Efficacy of Image-Guided Biopsy of Small Renal Masses

Cancers, Journal Year: 2024, Volume and Issue: 16(4), P. 835 - 835

Published: Feb. 19, 2024

Introduction: Image-guided renal mass biopsy is gaining increased diagnostic acceptance, but there are limited data concerning the safety and yield of for small masses (≤4 cm). This study evaluated safety, yield, management after image-guided percutaneous masses. Methods: A retrospective IRB-approved was conducted on patients who underwent histopathologic diagnosis at a single center from 2015 to 2021. Patients with prior history malignancy or >4 cm were excluded. Descriptive statistics used summarize patient demographics, tumor size, imaging modality biopsy, procedure details, complications, pathological diagnosis, post-biopsy management. considered successful when specimen sufficient without need repeat biopsy. Complications graded according SIR classification adverse events. chi-squared test (significance level set p ≤ 0.05) compare success rate biopsies in different lesion size groups. Results: total 167 met inclusion criteria. The median age 65 years (range: 26–87) 51% male. 2.6 one–four). Ultrasound solely employed 60% procedures, CT 33%, combination US/CT 6%, MRI one case. With on-site cytopathology, number specimens obtained per four one–nine). overall complication 5%. Grade complications seen 4% (n = 7), consisting perinephric hematoma 6) retroperitoneal 1). There grade B (0.5%; pain) D pyelonephritis). no mortality within 30 days post-biopsy. Biopsy 88% cases. sub-group analysis showed 85% tumors <3 93% ≥3 (p 0.01). Pathological diagnoses included cell carcinoma (65%), oncocytoma (18%), clear papillary (9%), angiomyolipoma (4%), xanthogranulomatous pyelonephritis (1%), lymphoma high-grade urothelial metanephric adenoma revealing benign 30% most common treatment surgery (40%), followed by cryoablation (22%). In total, 37% managed conservatively, received chemotherapy. Conclusion: demonstrates efficacy significantly higher 3–4 compared those cm. results high percentage informed decisions patients.

Language: Английский

---

Pre-operative imaging evaluation of renal cell carcinoma

Revista da Associação Médica Brasileira, Journal Year: 2024, Volume and Issue: 70(suppl 1)

Published: Jan. 1, 2024

---

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials

Materials Today Bio, Journal Year: 2024, Volume and Issue: 27, P. 101149 - 101149

Published: July 9, 2024

Renal cell carcinoma (RCC) is recognized as one of the three primary malignant tumors affecting urinary system, posing a significant risk to human health and life. Despite advancements in understanding RCC, challenges persist its diagnosis treatment, particularly early detection due issues low specificity sensitivity. Consequently, there an urgent need for development effective strategies enhance diagnostic accuracy treatment outcomes RCC. In recent years, with extensive research on materials applications biomedical field, some have been identified promising clinical applications, e.g., many tumors, including Herein, we summarize latest that are being studied applied While focusing their adjuvant effects, also discuss technical principles safety, thus highlighting value potential application. addition, limitations application these possible future directions, providing new insights improving RCC treatment.

Language: Английский

---

Early-Stage Renal Cell Carcinoma Locoregional Therapies: Current Approaches and Future Directions

Clinical Medicine Insights Oncology, Journal Year: 2024, Volume and Issue: 18

Published: Jan. 1, 2024

Renal cell carcinoma (RCC) is the most common primary renal malignancy. Prevalence of RCC in developed countries has slowly increased. Although partial or total nephrectomy been first-line treatment for early-stage RCC, improved similar safety and outcomes with locoregional therapies have challenged this paradigm. In review, we explore techniques including radiofrequency ablation, cryoablation, microwave ablation a focus on procedural technique, patient selection, safety/treatment outcomes. Furthermore, discuss future advances novel techniques, radiomics, combination therapy, high-intensity focused ultrasound, catheter-directed techniques.

Language: Английский

---

Clear cell likelihood score may improve diagnosis and management of renal masses

Abdominal Radiology, Journal Year: 2024, Volume and Issue: 49(12), P. 4494 - 4506

Published: June 20, 2024

Language: Английский

---

The role of CT-guided percutaneous biopsy in the diagnosis of suspected metastatic renal cell carcinoma – which location is the most suitable?

Videosurgery and Other Miniinvasive Techniques, Journal Year: 2024, Volume and Issue: unknown

Published: July 31, 2024

Systemic targeted therapy options are commonly used in patients with metastatic renal cell carcinoma (mRCC). Histological verification is crucial for treatment of mRCC. Our aim was to evaluate an optimal location percutaneous computed tomography‑guided biopsy a diagnosis suspected A total 138 biopsies tumors ranging from 21 133 mm diameter (median, 72 mm) were carried out 134 mRCC over 5‑year period. The variable, kidney performed 77 cases (55.8%), and other localizations (retroperitoneum, peritoneal cavity, liver, pelvis, pleural space, lung, mediastinum, chest or abdominal wall, pancreas) 61 (44.2%). As many as 288 (97.1%), yielded truepositive results, 4 procedures (2.9%) histologically falsenegative results that required confirmation through extended rebiopsy. RCC the most common individual (85.5%), non‑RCC histology verified 14.5% cases. In total, 32 complications (23.2%) confirmed, 2 which pneumothoraces, 29 minor bleeding needed only conservative management, 1 case angiography embolization hemorrhage treatment. While no significant relationship between success lesion localization (renal vs other) found (P = 0.13), complication rate 0.01). Lesion not relevant histological accuracy biop‑ sies However, lesions outside had lower rate.

Language: Английский

---

Treatment Modalities and Risks of Complication for Patients With Localized Renal Cell Carcinoma Aged 75 and Older

Journal of Surgical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 29, 2024

ABSTRACT Background and Objectives Partial (PN)/radical (RN) nephrectomy is the standard treatment for localized renal‐cell carcinoma (RCC). The potential risks of these procedures are concerns elderly. We evaluated perioperative outcomes/survival patients aged ≥ 75 years with RCC who underwent PN, RN, or thermal ablation (TA). Methods Localized undergoing PN/RN/TA (2000–2023) were retrospectively reviewed. Logistic‐regression assessed factors associated major complications. Kaplan‐Meier estimated survival. Results A total 278 (≥ years) received intervention (107RN, 101PN, 70TA) identified. Median age was 78 years. PN younger than other cohorts (77 vs. 79, p = 0.006). Patients cancer comorbidities TA PN/RN (93% 88%/76%, respectively). tumor size 4.0, 3.0, 2.6 cm in cohorts, respectively. RN had more complex masses compared to (9 7, < 0.001). Postoperative complications significantly greater among ( 0.03), but there no significant difference Clavien 3 Peripheral vascular disease (PVD) on multivariable analysis 0.03). performed at a stable rate while decreased favor TA. There RCC‐/non‐RCC‐specific survival modalities. Conclusions It important make informed decisions about treating elderly reduce morbidity/mortality. PVD could be determining factor favoring amenable tumors.

Language: Английский

---

Preoperative Risk Stratification of Renal Neoplasia: Are Classification Semantics Hindering Progress?

European Urology, Journal Year: 2023, Volume and Issue: 85(1), P. 72 - 73

Published: Oct. 17, 2023

Language: Английский

---